144 related articles for article (PubMed ID: 26872992)
21. A role for Rho-kinase in Ca-independent contractions induced by phorbol-12,13-dibutyrate.
Baek I; Jeon SB; Kim J; Seok YM; Song MJ; Chae SC; Jun JE; Park WH; Kim IK
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):256-61. PubMed ID: 18986333
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of NOX/VPO1 pathway and inflammatory reaction by trimethoxystilbene in prevention of cardiovascular remodeling in hypoxia-induced pulmonary hypertensive rats.
Liu B; Luo XJ; Yang ZB; Zhang JJ; Li TB; Zhang XJ; Ma QL; Zhang GG; Hu CP; Peng J
J Cardiovasc Pharmacol; 2014 Jun; 63(6):567-76. PubMed ID: 24492474
[TBL] [Abstract][Full Text] [Related]
23. Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs.
Lopez NC; Ebensperger G; Herrera EA; Reyes RV; Calaf G; Cabello G; Moraga FA; Beñaldo FA; Diaz M; Parer JT; Llanos AJ
Am J Physiol Regul Integr Comp Physiol; 2016 Jun; 310(11):R1053-63. PubMed ID: 26911462
[TBL] [Abstract][Full Text] [Related]
24. Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats.
Sun XZ; Tian XY; Wang DW; Li J
Eur Rev Med Pharmacol Sci; 2014; 18(7):959-64. PubMed ID: 24763873
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Rho-kinase Attenuates Left Ventricular Remodeling Caused by Chronic Intermittent Hypoxia in Rats via Suppressing Myocardial Inflammation and Apoptosis.
Wang ZH; Zhu D; Xie S; Deng Y; Pan Y; Ren J; Liu HG
J Cardiovasc Pharmacol; 2017 Aug; 70(2):102-109. PubMed ID: 28437280
[TBL] [Abstract][Full Text] [Related]
26. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.
Arita R; Hata Y; Nakao S; Kita T; Miura M; Kawahara S; Zandi S; Almulki L; Tayyari F; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Diabetes; 2009 Jan; 58(1):215-26. PubMed ID: 18840783
[TBL] [Abstract][Full Text] [Related]
27. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway.
Chen XY; Dun JN; Miao QF; Zhang YJ
Pharmacology; 2009; 83(2):67-79. PubMed ID: 19052484
[TBL] [Abstract][Full Text] [Related]
28. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
Kanda T; Wakino S; Hayashi K; Homma K; Ozawa Y; Saruta T
Kidney Int; 2003 Dec; 64(6):2009-19. PubMed ID: 14633123
[TBL] [Abstract][Full Text] [Related]
29. Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension.
Schwenke DO; Pearson JT; Sonobe T; Ishibashi-Ueda H; Shimouchi A; Kangawa K; Umetani K; Shirai M
J Appl Physiol (1985); 2011 Apr; 110(4):901-8. PubMed ID: 21212241
[TBL] [Abstract][Full Text] [Related]
30. Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of end‑stage pulmonary hypertension with left heart disease.
Zhuang R; Wu J; Lin F; Han L; Liang X; Meng Q; Jiang Y; Wang Z; Yue A; Gu Y; Fan H; Zhou X; Liu Z
Int J Mol Med; 2018 Sep; 42(3):1341-1352. PubMed ID: 29901088
[TBL] [Abstract][Full Text] [Related]
31. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats.
Koshikawa S; Nishikimi T; Inaba C; Akimoto K; Matsuoka H
J Hypertens; 2008 Sep; 26(9):1837-48. PubMed ID: 18698220
[TBL] [Abstract][Full Text] [Related]
32. [Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Jiang H; Guan RJ; Wang HY
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):239-44. PubMed ID: 23879951
[TBL] [Abstract][Full Text] [Related]
33. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip¹ via the ERK signal pathway.
Liu AJ; Ling F; Wang D; Wang Q; Lü XD; Liu YL
Chin Med J (Engl); 2011 Oct; 124(19):3098-104. PubMed ID: 22040563
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells.
Xie Z; Su W; Guo Z; Pang H; Post SR; Gong MC
Cardiovasc Res; 2006 Feb; 69(2):491-501. PubMed ID: 16336954
[TBL] [Abstract][Full Text] [Related]
35. Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Sun XZ; Li SY; Tian XY; Wu QQ
Int J Clin Exp Pathol; 2015; 8(8):9517-21. PubMed ID: 26464714
[TBL] [Abstract][Full Text] [Related]
36. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Gupta N; Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Mol Pharm; 2017 Mar; 14(3):830-841. PubMed ID: 28165252
[TBL] [Abstract][Full Text] [Related]
37. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil.
Dai ZK; Wu BN; Chen IC; Chai CY; Wu JR; Chou SH; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2011 Jan; 46(1):45-59. PubMed ID: 20717937
[TBL] [Abstract][Full Text] [Related]
38. Dexfenfluramine discontinuous treatment does not worsen hypoxia-induced pulmonary vascular remodeling but activates RhoA/ROCK pathway: consequences on pulmonary hypertension.
Desbuards N; Antier D; Rochefort GY; Apfeldorfer CS; Schenck E; Hanton G; Hyvelin JM
Eur J Pharmacol; 2009 Jan; 602(2-3):355-63. PubMed ID: 19049806
[TBL] [Abstract][Full Text] [Related]
39. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT
Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
